Padcev Access Challenges: What Providers and Prescribers Need to Know in 2026

Since its full FDA approval in December 2023 for locally advanced or metastatic urothelial cancer in combination with pembrolizumab, Padcev (enfortumab vedotin-ejfv) has become a cornerstone treatment for urothelial carcinoma. The EV-302/KEYNOTE-A39 trial demonstrated a median overall survival of 31.5 months with EV + pembrolizumab versus 16.1 months with platinum-based chemotherapy (HR 0.47; p<0.0001).

Despite this transformative efficacy data, many patients face significant barriers to initiating and maintaining Padcev therapy. This guide reviews the most common access challenges oncology teams encounter and how to navigate them efficiently in 2026.

FDA-Approved Indications for Padcev in 2026

As of 2026, Padcev carries the following FDA-approved indications:

In combination with pembrolizumab (or pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and continued after cystectomy as adjuvant treatment, for adult MIBC patients ineligible for cisplatin

In combination with pembrolizumab (or pembrolizumab and berahyaluronidase alfa-pmph), for adult patients with locally advanced or metastatic urothelial cancer (la/mUC)

As monotherapy for la/mUC in patients who have received a PD-1/PD-L1 inhibitor and platinum-based chemotherapy, or who are cisplatin-ineligible with ≥1 prior line of therapy

Prior Authorization: Strategies to Reduce Delays

Prior authorization (PA) is the most common source of treatment delays. To minimize PA turnaround time:

Submit complete documentation from the start: Include pathology confirming urothelial carcinoma, staging, ECOG performance status, cisplatin eligibility assessment, and prior treatment history

Use PADCEV Support Solutions: Call 1-888-402-0627 or log into the Prescriber Portal to enroll patients and receive PA support, including help with appeal submissions

Enroll Access and Reimbursement Manager (ARM): Your PADCEV Sales Representative can connect you with a dedicated ARM who specializes in access and reimbursement support

Prepare for appeals: If PA is denied, PADCEV Support Solutions can provide guidance on the required documentation for a formal appeal, including clinical evidence from EV-302

J-Code Billing: Getting Reimbursement Right

Padcev is billed under the medical benefit using HCPCS code J9177. Important billing details:

1 billing unit of J9177 = 0.25 mg enfortumab vedotin-ejfv

80 units = 1 single-dose 20 mg vial; 120 units = 1 single-dose 30 mg vial

Actual units reported vary based on each patient's body weight and calculated dose

NDC: 20 mg vial — 51144-020-01; 30 mg vial — 51144-030-01

Errors in J-code billing are a common cause of reimbursement denials. PADCEV Support Solutions provides a Billing and Coding Guide as a downloadable resource for your office.

Monitoring Requirements That Affect Scheduling

Padcev requires proactive monitoring that can affect clinic scheduling and patient preparation:

Blood glucose monitoring: Hyperglycemia is a significant risk, especially in patients with diabetes or high BMI. Withhold Padcev if glucose >250 mg/dL. Exclude patients with baseline HbA1c ≥8%.

Skin reaction monitoring: SJS/TEN occurs predominantly in the first cycle. Educate patients to report rash immediately. Consider dermatology referral for Grade ≥2 skin reactions.

Peripheral neuropathy assessment: Grade ≥2 peripheral neuropathy warrants dose modification. Higher MMAE exposure correlates with higher neuropathy incidence.

Ocular examinations: Consider ophthalmology referral for patients reporting dry eye, blurred vision, or conjunctivitis.

39,483+ patients found their medications in stock

39K+

Find Padcev In Stock Today →

Key Drug Interactions Clinicians Must Know

MMAE (the cytotoxic payload of Padcev) is primarily metabolized by CYP3A4. Clinically significant interactions:

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, grapefruit): Avoid — increase free MMAE exposure and toxicity risk

Strong CYP3A4 inducers (apalutamide, rifampin, enzalutamide): May decrease MMAE levels — use with caution and monitor efficacy

Hepatic impairment: Avoid use in patients with moderate or severe hepatic impairment (Child-Pugh B or C)

How medfinder Helps Your Patients

medfinder for providers is a service that calls pharmacies and infusion facilities on your patient's behalf to check which ones can fill or administer their prescribed medication. If a patient is struggling to find an available infusion center or confirm drug availability before their scheduled dose, medfinder can rapidly identify available facilities and deliver results by text.

See also: How to Help Your Patients Find Padcev in Stock: A Provider's Guide.